Company intelligence / Profile preview

Vertiflex

Carlsbad, California, United Statesbostonscientific.com ↗

Ownership: Private
Development stage: Commercial

Overview

The Superion Indirect Decompression System by Vertiflex has demonstrated long-term safety and efficacy for moderate lumbar spinal stenosis. Clinical trials—including a pivotal randomized controlled trial with over 470 patients—showed significant improvements in leg and back pain, high patient satisfaction rates (~90%), opioid reduction (~85%), and durable results up to five years post-procedure. The device met its primary clinical endpoint of noninferiority compared to Medtronic’s X‑Stop Spacer at two years.

Therapeutic areas: Neurology
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Superion Indirect Decompression System

Commercial

Indications: Lumbar spinal stenosis

Partnerships

None publicly disclosed beyond acquisition/investors.

Beyond the preview

Go deeper on Vertiflex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vertiflex.

Explore the full profile